SGLT2阻害薬
“Drug–Drug Interactions with Sodium-Glucose Cotransporters Type 2 (SGLT2) Inhibitors, New Oral Glucose-Lowering Agents for the Management of Type 2 Diabetes Mellitus”. Clinical Pharmacokinetics 53 (4): 295–304. doi:10.1007/s40262-013-0128-8. hdl:2268/164207. PMID 24420910. http://orbi.ulg.ac.be/handle/2268/164207.
1 2 Bhartia, Mithun; Tahrani, Abd A.; Barnett, Anthony H. (2011). “SGLT-2 Inhibitors in Development for Type 2 Diabetes Treatment”. The Review of Diabetic Studies 8 (3): 348–354. doi:10.1900/RDS.2011.8.348. PMC 3280669. PMID 22262072. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3280669/.
↑ Yang, Li; Li, Haiyan; Li, Hongmei; Bui, Anh; Chang, Ming; Liu, Xiaoni; Kasichayanula, Sreeneeranj; Griffen, Steven C. et al. (2013).
グリフロジンは、in vitro、前臨床試験および臨床試験において、心臓、肝臓、腎臓の保護作用、抗高脂血症作用、抗動脈硬化作用、抗肥満作用、抗新生物作用を示すと想定されている。この系統の薬剤の多面的な効果は、ナトリウム利尿(英語版)、血液濃縮、レニン-アンジオテンシン-アルドステロン系の不活性化、ケトン体形成、エネルギー恒常性の変化、糖尿、脂肪分解、抗炎症、抗酸化作用などのさまざまな薬力学的作用によるものと考えられている。
1 2 3 Shubrook, Jay; Baradar-Bokaie, Babak; Adkins, Sarah (2015). “Empagliflozin in the treatment of type 2 diabetes: Evidence to date”. Drug Design, Development and Therapy 9: 5793–803. doi:10.2147/DDDT.S69926. PMC 4634822. PMID 26586935. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4634822/.
↑ Usman, Muhammad Shariq; Siddiqi, Tariq Jamal; Memon, Muhammad Mustafa; Khan, Muhammad Shahzeb; Rawasia, Wasiq Faraz; Talha Ayub, Muhammad; Sreenivasan, Jayakumar; Golzar, Yasmeen (2018). “Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: A systematic review and meta-analysis”. European Journal of Preventive Cardiology 25 (5): 495–502. doi:10.1177/2047487318755531. PMID 29372664.
“Pharmacokinetic and Pharmacodynamic Properties of Single- and Multiple-Dose of Dapagliflozin, a Selective Inhibitor of SGLT2, in Healthy Chinese Subjects”. Clinical Therapeutics 35 (8): 1211–1222.e2. doi:10.1016/J.Clinthera.2013.06.017. PMID 23910664.
↑ Chao, E. C. (2014). “SGLT-2 Inhibitors: A New Mechanism for Glycemic Control”. Clinical Diabetes 32 (1): 4–11. doi:10.2337/diaclin.32.1.4. PMC 4521423. PMID 26246672. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4521423/.
1 2 3 Anderson, Sarah L.; Marrs, Joel C. (2012). “Dapagliflozin for the Treatment of Type 2 Diabetes”. Annals of Pharmacotherapy 46 (4): 590–598. doi:10.1345/aph.1Q538. PMID 22433611.
1 2 3 Li, An-Rong; Zhang, Jian; Greenberg, Joanne; Lee, Taeweon; Liu, Jiwen (2011).
“Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors with All-Cause Mortality in Patients with Type 2 Diabetes”. JAMA 319 (15): 1580–1591. doi:10.1001/jama.2018.3024. PMC 5933330. PMID 29677303. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5933330/.
↑ Nashawi, Mouhamed; Sheikh, Omar; Battisha, Ayman; Ghali, Abdullah; Chilton, Robert (May 2021). “Neural tone and cardio-renal outcomes in patients with type 2 diabetes mellitus: a review of the literature with a focus on SGLT2 inhibitors”. Heart Failure Reviews 26 (3): 643–652. doi:10.1007/s10741-020-10046-w. ISSN 1573-7322. PMID 33169337.